Literature DB >> 20142302

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Marieke Liem-Moolenaar1, Erik T te Beek, Marieke L de Kam, Kari L Franson, René S Kahn, Ron Hijman, Daan Touw, Joop M A van Gerven.   

Abstract

In this study, the hypothesis that haloperidol would lead to an amelioration of Δ9-tetrahydrocannabinol (THC)-induced 'psychotomimetic' effects was investigated. In a double-blind, placebo-controlled, partial three-way crossover ascending dose study the effects of THC, haloperidol and their combination were investigated in 35 healthy, male mild cannabis users, measuring Positive and Negative Syndrome Scale, Visual Analogue Scales for alertness, mood, calmness and psychedelic effects, saccadic and smooth pursuit eye measurements, electroencephalography, Body Sway, Stroop test, Visual and Verbal Learning Task, hormone levels and pharmacokinetics. Compared with placebo, THC significantly decreased smooth pursuit, Visual Analogue Scales alertness, Stroop test performance, immediate and delayed word recall and prolactin concentrations, and significantly increased positive and general Positive and Negative Syndrome Scale score, Visual Analogue Scales feeling high, Body Sway and electroencephalography alpha. Haloperidol reversed the THC-induced positive Positive and Negative Syndrome Scale increase to levels observed with haloperidol alone, but not THC-induced 'high' feelings. Compared with placebo, haloperidol significantly decreased saccadic peak velocity, smooth pursuit, Visual Analogue Scales mood and immediate and delayed word recall and significantly increased Body Sway, electroencephalography theta and prolactin levels. THC-induced increases in positive Positive and Negative Syndrome Scale but not in Visual Analogue Scales feeling high were reversed by haloperidol. This indicates that psychotic-like effects induced by THC are mediated by dopaminergic systems, but that other systems are involved in 'feeling high'. Additionally, the clear reductions of psychotic-like symptoms by a clinically relevant dose of haloperidol suggest that THC administration may be a useful pharmacological cannabinoid model for psychotic effects in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142302     DOI: 10.1177/0269881109358200

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  20 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

Review 2.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 3.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

Review 4.  The effects of fall-risk-increasing drugs on postural control: a literature review.

Authors:  Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

Review 5.  Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives.

Authors:  Alison C Burggren; Anaheed Shirazi; Nathaniel Ginder; Edythe D London
Journal:  Am J Drug Alcohol Abuse       Date:  2019-07-31       Impact factor: 3.829

Review 6.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

7.  Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems.

Authors:  Nathalie Ginovart; Benjamin B Tournier; Marcelle Moulin-Sallanon; Thierry Steimer; Vicente Ibanez; Philippe Millet
Journal:  Neuropsychopharmacology       Date:  2012-06-13       Impact factor: 7.853

8.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

9.  Profiling the subjective effects of Δ⁹-tetrahydrocannabinol using visual analogue scales.

Authors:  Daniël Kleinloog; Frits Roozen; Willem De Winter; Jan Freijer; Joop Van Gerven
Journal:  Int J Methods Psychiatr Res       Date:  2014-02-05       Impact factor: 4.035

10.  Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study.

Authors:  Christina Andreou; Steffen Moritz; Kristina Veith; Ruth Veckenstedt; Dieter Naber
Journal:  Schizophr Bull       Date:  2013-05-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.